“…In particular, when the β -hCG level at the time of diagnosis was higher than 20,000 mIU/ml, or when β -hCG level after local MTX injection was elevated, additional systemic MTX administration was performed [5]. However, systemic MTX administration can cause complications, such as nausea, stomatitis, alopecia, bone marrow, depression, and pneumonitis [9]. Therefore, it would be beneficial if local treatment without systemic MTX was sufficient to treat CSP with higher β -hCG levels.…”